ClinicalTrials.gov
public full text
Public Domain
Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)#866037
- Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer#872040
- Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer#886457
- A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer#1032747
- Prognostic Significance of Number of Liver Metastases in Patients With Advanced Pancreatic Cancer Receiving Nab-paclitaxel Plus Gemcitabine.#636330
Record · ID 1293792
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive